India's Sun brings home Taro CEO as business plan accelerates

Indian flag

Mumbai-based Sun Pharmaceutical Industries has decided to bring the CEO of its Taro unit--Kal Sundaram--back from the U.S. to the head office in India by the end of the year as plans to consolidate manufacturing and other operations ramp up. 

Sundaram headed Taro following an acrimonious takeover effort by Sun's MD and founder, Dilip Shanghvi, from the Israel-based founders that ended in 2010.

He helped steer the previously unprofitable company to sales of $950 million in the year ending March of this year, with net profit hitting $450 million, according to the Economic Times.

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track," and in particular lauded progress in the U.S. market.

A replacement for Sundaram at Taro and the exact title of his new role at headquarters were not announced.

- here's the release
- and a story from the Economic Times

Related Articles:
India's Sun says consolidation efforts on track, eyes share buyback

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.